WASHINGTON (AP) — Federal regulators say approval of the first generic version of cancer drug Doxil will help resolve a lingering shortage triggered by manufacturing deficiencies.
The shortage of the Johnson & Johnson injectable medication, made under contract by Ben Venue Laboratories, has continued on and off for a few years. It's resulted in rationing, with some patients with ovarian and other cancers getting less-effective care, and disrupted studies testing Doxil against possible new treatments.
The Food and Drug Administration says it's approved a generic version, called doxorubicin, made by Sun Pharma Global FZE. Last February, the FDA authorized temporary importation from India of a brand-name version, called Lipodox, also made by Sun Pharma. It's a subsidiary of an Indian drugmaker.
Meanwhile, J&J continues to seek a contract manufacturer to replace Ben Venue.
Ruling In "Assault Weapons" Case Could Gut Gun Control Nationwide
Donald Trump Cancels All New Hampshire Events Today | RedState
The Remainderman | Human Events
'Not enough eye bleach on earth' to erase what Hillary just did in public [Vine]
Separate Bank Accounts Will Help Protect Newlyweds
Meanwhile, the F-35 is still a train wreck
Email Scandal Spin: No, Hillary, Powell and Rice Didn't 'Do It Too'